Glycomic therapeutics market projected to reach $424.67B by 2030 at 17.6% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Growth In Market Value Is Expected For The Glycomic Therapeutics Market Between 2026 And 2030?

The glycomic therapeutics market has experienced significant expansion recently. Projections indicate a rise from $189.51 billion in 2025 to $221.98 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.1%. Historically, this growth can be ascribed to progress in glycobiology research, the development of enzyme therapies, approvals for rare disease drugs, increased academic research funding, and expansion in biologics manufacturing.

The glycomic therapeutics market is projected to experience swift expansion in the coming years. This market is set to reach $424.67 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 17.6%. Factors driving this growth during the forecast period include the increasing adoption of precision medicine, advancements in glycan biomarker discovery, the broadening of orphan drug pipelines, innovations in synthetic biology, and a rise in pharmaceutical research investment. Key trends anticipated within the forecast period encompass the expansion of glycan-based drug development, an escalating emphasis on immune modulation therapies, greater utilization of enzyme replacement therapies, intensified research into rare and metabolic diseases, and the advancement of synthetic glycan technologies.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Which Key Drivers Are Affecting The Glycomic Therapeutics Market Development?

The growing occurrence of diabetes is projected to stimulate the expansion of the glycomic therapeutics market. Diabetes is a long-term health condition that impacts the body’s ability to regulate its blood sugar (glucose). In this condition, alterations in glycans have been noted, which can contribute to insulin resistance and various metabolic irregularities. Furthermore, specific glycan patterns serve as crucial biomarkers for the diagnosis of diabetes, the prediction of its progression, and the monitoring of treatment outcomes. For instance, according to GOV.UK, a UK-based non-profit government organization, it was reported in March 2025 that the prevalence of type 2 diabetes among adults aged 17 and over in England, as recorded by GPs, reached 7.0% in March 2024, up from 6.8% in March 2023. Therefore, the increasing prevalence of diabetes is a significant driver for the glycomic therapeutics market.

What Are The Key Segment Divisions In The Glycomic Therapeutics Market Segment Structure?

The glycomic therapeutics market covered in this report is segmented –

1) By Class: Isolated, Synthetic

2) By Structures: Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans, Targeting Glycosphingolipids, Other Structures

3) By Mode Of Action: Inhibits Neuraminidase, Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate, Erythropoietin And Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase, Interleukin 1, 2 And 3, Beta And Gamma Interferons, Other Mode Of Action

4) By Indications: Thrombosis And Chemoprophylaxis, Anemia, Anti-Adhesive And Anti-Inflammatory, Cataracts, Gaucher’s Disease, Mps-1 And IV, Cancer, Alzheimer’s Disease, Influenza Type A And B, Other Indications

Subsegments:

1) By Isolated: Natural Glycans, Glycan Derivatives, Glycoproteins

2) By Synthetic: Chemically Synthesized Glycans, Recombinant Glycans, Glycopeptides

What Trends Are Transforming The Glycomic Therapeutics Market?

Leading companies within the glycomic therapeutics market are concentrating on developing innovative solutions, such as glyco-immune checkpoint inhibitors, to overcome tumor immune evasion and enhance treatment efficacy. These inhibitors are therapies crafted to block immunosuppressive sugar molecules on cancer cells, thereby assisting the immune system in better recognizing and attacking tumors. For instance, in June 2023, Palleon Pharmaceuticals Inc., a US-based biopharmaceutical company, announced the dosing of the first patient in the combination therapy cohort of the Phase 1/2 GLIMMER-01 clinical trial. This trial is evaluating their lead glyco-immunology candidate E-602 in combination with cemiplimab (Libtayo®) in patients with advanced cancers. The study examines E-602 as both a monotherapy and combined with cemiplimab to assess its safety, pharmacodynamics, and antitumor activity. E-602 is a first-in-class glyco-immune checkpoint inhibitor designed to enzymatically degrade immunosuppressive sialoglycans on tumor and immune cells, with the aim of restoring antitumor immunity.

Which Organizations Are Engaged In The Glycomic Therapeutics Market?

Major companies operating in the glycomic therapeutics market are F Hoffmann-La Roche Ltd., Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ludger Ltd, GlycoMar Limited

Get The Full Glycomic Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Which Region Holds The Highest Market Share In The Glycomic Therapeutics Market?

North America was the largest region in the glycomic therapeutics in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Glycomic Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Glycomic Therapeutics Market 2026, By The Business Research Company

Glycol Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycol-global-market-report

Glycomics Or Glycobiology Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycomics-or-glycobiology-global-market-report

Glycopeptide Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795